Agena Bioscience in the News

Agena Bioscience Introduces New Lung and Colon Cancer Panels for Detection of Somatic Mutations from Liquid Biopsies and Solid Tumor Tissues

15 March 2017

SAN DIEGO, Calif., March 15, 2017 — Agena Bioscience today introduced new targeted research panels for the detection of somatic mutations from lung and colon cancers. The UltraSEEK™ Lung and Colon Panels enable detection of mutations as low as 0.1% minor allele frequency (MAF) from circulating tumor cells (CTCs)... Read More

Multiplexed Analysis of ALK, ROS1, and RET Rearrangements in Lung Cancer Enabled by the MassARRAY^® System

9 February 2017

SAN DIEGO, Calif., February 9, 2017 – Agena Bioscience today announced a comparative study published in Scientific Reports highlighting the use of its mass spec-based platform for transcriptome analysis of ALK, ROS1, and RET gene fusions in lung cancer. While Fluorescence In Situ Hybridization (FISH) is the gold standard... Read More

Agena Bioscience Names Genelex as Certified Service Provider for Targeted Genetic Analysis

29 August 2016

SAN DIEGO, Calif., August 29, 2016 — Agena Bioscience today announced the successful certification of Genelex as a Certified Service Provider of the MassARRAY® technology. The MassARRAY System is used to identify and validate SNPs, INDELs, CNV’s, translocations, somatic mutations, including rare variants, and methylation profiles across a variety... Read More

David Coorey Joins Agena Bioscience to Lead Europe, Middle East, and Africa Business

11 July 2016

SAN DIEGO, Calif., July 11, 2016 — Agena Bioscience today announced the appointment of David Coorey as Vice President and Managing Director, EMEA. David joins Agena Bioscience from Becton Dickinson, where he most recently held the position of Business Unit Director for the Diagnostic Systems Division. David brings over 20... Read More

Agena Bioscience Launches High Sensitivity and Multiplexed Genetic Testing Product for Targeted Analysis of Solid Tumors

18 April 2016

iPLEX® HS chemistry enables multiplex detection down to 1% allele frequency SAN DIEGO, Calif., April 18, 2016 — Today Agena Bioscience announced the commercial availability of iPLEX® HS, a new chemistry that enables highly sensitive, multiplexed detection of genetic variants present in solid tumors. iPLEX HS, unveiled today at... Read More

Agena Bioscience Launches in vitro Diagnostic Tests for Lung and Colon Cancer in Europe

4 April 2016

Company achieves CE-IVD mark and enters routine molecular diagnostics market SAN DIEGO, Calif. and Hamburg, Germany, April 4, 2016 — Agena Bioscience today announced the launch of its CE-IVD marked MassARRAY® Dx products in Europe. Two targeted diagnostic panels will be sold, the MassARRAY Dx Lung Panel and the... Read More

Agena Bioscience and CapitalBio Technology to Develop Cost-Effective Genetic Testing for Commercial Agricultural Applications

1 March 2016

SAN DIEGO, Calif., March 1, 2016 – Agena Bioscience (Agena) today announced its partnership to co-develop commercial tests with CapitalBio Technology (CapitalBio) for a variety of agricultural applications on the MassARRAY® System. The tests will be made available as certified services through CapitalBio. “CapitalBio has established a strong presence... Read More

Agena Bioscience Partners with DaRui Biotech to Bring MassARRAY Technology to the Diagnostics Market in China

1 February 2016

SAN DIEGO, Calif., February 1, 2016 – Agena Bioscience today announced its partnership with DaRui Biotechnology to co-develop a menu of in vitro diagnostic tests for oncology and inherited diseases on its MassARRAY® System for targeted genetic analysis. “The China Market is a significant opportunity for Agena Bioscience, representing... Read More

Agena Bioscience Announces the Expansion of its Headquarters in San Diego, California, to Better Serve its Growing Customer Base

11 January 2016

SAN DIEGO, Calif., January 11, 2016 — Agena Bioscience today announced the expansion of its headquarters to a new site in San Diego. Located at 4755 Eastgate Mall, the new 55,000-square-foot facility houses the company’s laboratory, manufacturing, and office workforce. “We’re tremendously excited about moving our headquarters into a... Read More

Agena Bioscience and Diatech Pharmacogenetics Announce Plan to Launch Actionable, Targeted CE-IVD Marked Oncology Assays for Colon, Lung, and Melanoma Treatment

27 October 2015

SAN DIEGO, Calif., Oct. 27, 2015 — Agena Bioscience announced today the planned commercial launch of its CE-IVD marked MassARRAY® Dx PLUS assays for gene-specific mutation testing to aid in the selection of targeted therapy regimens. Agena Bioscience will introduce the first diagnostic kits in partnership with Diatech Pharmacogenetics.... Read More